AIkido Pharma Announces Dr. Matt Frieman's Appearance on This Week in Virology
AIkido Pharma Inc. (Nasdaq: AIKI) announced Dr. Matt Frieman's recent appearance on the podcast This Week in Virology, where he discussed the Covid-19 pandemic as a coronavirologist. At the 42-minute mark, he emphasized the future prospects of virology, particularly AIkido's pan-viral initiative. The company is committed to developing a family of pan-viral drugs alongside industry leaders. AIkido Pharma focuses on a diverse portfolio of anti-cancer therapeutics and broad-spectrum antiviral platforms targeting multiple viruses, including SARS-CoV and Ebolavirus.
- Collaboration with Dr. Frieman and industry leaders on pan-viral drug development.
- Research focus on broad-spectrum antiviral drugs that may inhibit several viruses.
- A diverse pipeline of anti-cancer therapeutics targeting unmet medical needs.
- None.
NEW YORK, March 12, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Matt Frieman appeared on the video podcast This Week in Virology, segment entitled "TWiV 729: A floret of spikes with Matt Frieman." In the video, Dr. Frieman discusses the Covid-19 pandemic from the point of view of a coronavirologist.
The entire video can be seen here: https://www.microbe.tv/twiv/
At the forty-two minute mark, Dr. Frieman discusses the future of this type of virology work and his work on the pan-viral initiative with AIkido Pharma. The Company is proud to be working with industry leaders like Dr. Frieman in the development of a family of pan-viral drugs.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: info@aikidopharma.com
www.aikidopharma.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-announces-dr-matt-friemans-appearance-on-this-week-in-virology-301246460.html
SOURCE AIkido Pharma Inc.
FAQ
What did Dr. Matt Frieman discuss on This Week in Virology?
What is the focus of AIkido Pharma's research initiatives?
What viruses is AIkido Pharma's antiviral platform targeting?
What date was the press release issued?
What is the stock symbol of AIkido Pharma?
